Changing the future of Oncology.
About Sutro Biopharma
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Platform
Precision protein engineering generates superior molecules
Products
4 product candidates in the clinic as a result of research innovations
Partners
Premier collaborations with Bristol Myers Squibb, Merck, EMD Serono and Vaxcyte (formerly known as SutroVax)
People
Great people making excellence happen, every day!
Technology
Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify optimal molecules designed for safety and potency.
Pipeline
Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways.
Partnerships
Recent News
Sutro Biopharma to Participate in the 12th Annual Wedbush PacGrow Healthcare Virtual Conference
SOUTH SAN FRANCISCO, Calif., July 29, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Nicki Vasquez, SVP Alliance Management/Portfolio Strategy and Operations Interviewed by Elaine Quilici of Pharmaceutical Executive – “Firsthand Views: Latinos in Pharma”
Pharmaceutical Executive Firsthand Views: Latinos in Pharma https://www.pharmexec.com/view/firsthand-views-latinos-in-pharma July 8, 2021 Elaine Quilici Latino executives share their experiences and insights on the community’s contributions to the life sciences...
Bill Newell, CEO Interviewed by Peter Hofland of The Onco’Zine Brief – “Antibody-Drug Conjugates: Coming of Age”
In this episode of The Onco’Zine Brief, developed in collaboration with ADC Review | Journal of Antibody-drug Conjugates (at www.ADCReview.com), Peter Hofland, Ph.D. talks with William (Bill) Newell, JD, Chief Executive Officer and a member of the Board of Directors...
Careers and Culture
At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference in the lives of patients, both as individuals and as part of a team.
